Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Fatigue Difficult to Isolate From Related Cancer Symptoms

August 1, 2001
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 8
Volume 10
Issue 8

PHILADELPHIA-A study presented at the Oncology Nursing Society’s 26th Annual Congress in San Diego underscores the challenge of managing cancer-related fatigue: Fatigue frequently is part of a cluster of interrelated symptoms, such as pain, depression, and poor sleep quality.

PHILADELPHIA—A study presented at the Oncology Nursing Society’s 26th Annual Congress in San Diego underscores the challenge of managing cancer-related fatigue: Fatigue frequently is part of a cluster of interrelated symptoms, such as pain, depression, and poor sleep quality.

Andrea M. Barsevick, DNSc, RN, director of nursing research and education, Fox Chase Cancer Center, and her colleagues examined the effects of symptom clustering in a group of 101 patients who were drawn from the control group of a larger study of fatigue management.

The study group was composed of 89 women and 12 men, with a mean age of 57 (range, 30 to 78). The majority of patients had breast cancer, but other diagnoses included cervical cancer, lymphoma, and lung cancer. All disease stages were represented in the group.

The investigators measured fatigue, pain, depression, and sleep quality at baseline and at a time of expected high fatigue (at the end of 5 weeks of radiation therapy or 48 hours after the second cycle of chemotherapy).

Fatigue was measured with the Profile of Mood States (fatigue scale), the Schwartz Cancer Fatigue Scale, and the General Fatigue Scale.

Sleep quality was assessed with the Pittsburgh Sleep Quality Scale; depression, with the Profile of Mood States (depression scale); and pain, with a Side Effects Checklist item (pain).

When the symptoms were considered individually, 36% of the study participants experienced pain; 82% had sleep disturbances; 22% experienced depression; and 81% experienced fatigue.

When the symptoms were grouped as triads, 7% of the patients had fatigue-pain-depression; 21% had fatigue-pain-sleep disturbance; 7% experienced pain-sleep disturbance-depression; and 21% had fatigue-sleep disturbance-depression. Seven percent of the patients experienced all four symptoms.

The investigators concluded that symptom clustering is common among patients undergoing cancer treatment and that fatigue is significantly correlated with depression. Poor sleep quality also was associated with fatigue, but the relationship did not reach statistical significance.

The study did not find a correlation between fatigue and pain, but the researchers noted that the pain measurement may not have been sensitive enough.

Articles in this issue

Amifostine Can Reduce Xerostomia, Loss of Taste, Fibrosis, and Pain
Three-Dimensional Conformal Radiation Therapy Reduces Rectal Damage in Prostate Cancer Treatment
Can Concurrent Amifostine and 5-FU Permit Delivery of Higher Boost Doses of Radiation?
Preventing Severe Esophagitis Critical in Chemoradiotherapy for Lung Cancer
Upcoming Trial to Test Ability of Amifostine to Reduce Radiation-Induced Hypothyroidism
Amifostine Offers Little Advantage in Small Trial of Twice-Daily Radiation Plus Chemotherapy
Subcutaneous Amifostine Provides Protection Against Radiation-Induced Acute Xerostomia
Study to Test Amifostine in Cervical Cancer Patients Treated With Combined-Modality Therapy
Radioprotectants May Extend Use of Combined Chemotherapy and Radiation
Amifostine Ameliorates Pneumonitis and Esophagitis During Radiochemotherapy
Potentially Useful Predictors of Risk for Developing Postradiation Pneumonitis
Amifostine Trial Represents First FDA Approval of Treatment Interacting With Radiation
Amifostine Reduces Side Effects During Treatment for Advanced Lung Cancer
Intrarectal Amifostine Prevents Late Rectal Complications of Radiotherapy for Prostate Cancer
Experts Consider Statistical Issues in Designing Studies of Toxicity Modifiers
Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Related Content
Advertisement

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 12th 2025
Article

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 12th 2025
Article

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.


Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.


We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

Related Content
Advertisement

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 12th 2025
Article

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 12th 2025
Article

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.


Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.


We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.